Davern Capital Partners, LP
NY, NY
$587m in 15 US stocks at the end of 30 June 2026. The top 10 are 86.8% of the money. It changed about 33.2% of the portfolio this quarter.
Value
$587m
Stocks
15
Top 10 share
86.8%
Turnover
33.2%
What changed this quarter
New
Bought for the first time this quarter.
- Alnylam PharmaceuticalsALNY5.8% of the fund
- Vera TherapeuticsVERA3.6% of the fund
- Avalo TherapeuticsAVTX1.5% of the fund
Added
Bought more of a stock they already held.
- Biontech SEBNTX12.0% of the fund+147%
- Roivant SciencesROIV11.7% of the fund+121%
- Royalty PharmaRPRX11.0% of the fund+122%
- Ionis PharmaceuticalsIONS10.8% of the fund+106%
- InsmedINSM10.2% of the fund+207%
- Regeneron PharmaceuticalsREGN9.8% of the fund+107%
- Structure TherapeuticsGPCR4.1% of the fund+253%
- Mineralys TherapeuticsMLYS4.0% of the fund+92%
- Generate BiomedicinesGENB2.4% of the fund+39%
- PROCEPT BioRoboticsPRCT1.8% of the fund+78%
Cut
Sold some of their stake.
- Legend BiotechLEGN5.9% of the fund-9%
- NateraNTRA5.5% of the fund-17%
Sold out
Sold their entire stake.
- PfizerPFE-100%
- Argenx SEARGX-100%
- Eli LillyLLY-100%
- Abivax SAABVX-100%
- Viridian TherapeuticsVRDN-100%
Holdings
- Biontech SEBNTX
- Share
- 12.0%
- Value
- $70m
- Shares
- 754,550
+147%
- Legend BiotechLEGN
- Share
- 5.9%
- Value
- $34m
- Shares
- 1,191,522
-9%
- Structure TherapeuticsGPCR
- Share
- 4.1%
- Value
- $24m
- Shares
- 446,059
+253%
- Generate BiomedicinesGENB
- Share
- 2.4%
- Value
- $14m
- Shares
- 824,679
+39%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Biontech SEBNTX | 12.0% | $70m | 754,550 | +147% |
| Roivant SciencesROIV | 11.7% | $68m | 1,932,904 | +121% |
| Royalty PharmaRPRX | 11.0% | $65m | 1,155,809 | +122% |
| Ionis PharmaceuticalsIONS | 10.8% | $63m | 798,709 | +106% |
| InsmedINSM | 10.2% | $60m | 559,824 | +207% |
| Regeneron PharmaceuticalsREGN | 9.8% | $58m | 92,640 | +107% |
| Legend BiotechLEGN | 5.9% | $34m | 1,191,522 | -9% |
| Alnylam PharmaceuticalsALNY | 5.8% | $34m | 113,085 | New |
| NateraNTRA | 5.5% | $32m | 118,975 | -17% |
| Structure TherapeuticsGPCR | 4.1% | $24m | 446,059 | +253% |
| Mineralys TherapeuticsMLYS | 4.0% | $23m | 858,753 | +92% |
| Vera TherapeuticsVERA | 3.6% | $21m | 498,832 | New |
| Generate BiomedicinesGENB | 2.4% | $14m | 824,679 | +39% |
| PROCEPT BioRoboticsPRCT | 1.8% | $10m | 464,920 | +78% |
| Avalo TherapeuticsAVTX | 1.5% | $9m | 468,666 | New |
Over time and by industry
Value over time
Dec '25
Jun '26
Value is up 89.6% since 31 December 2025.
Where the money is
Health care78.1%
Other21.9%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.